Rasagiline

Overview

Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The drug is taken by mouth.[1][2][3] WP

Side effects of rasagiline include insomnia and orthostatic hypotension, among others. Rasagiline acts as an inhibitor of the enzyme monoamine oxidase (MAO) and hence is a monoamine oxidase inhibitor (MAOI). More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B). The drug is thought to work by increasing levels of the monoamine neurotransmitter dopamine in the brain. Rasagiline shows pharmacological differences from the related drug selegiline, including having no amphetamine-like metabolites, monoamine-releasing activity, or monoaminergic activity enhancer actions, which may result in clinical differences between the medications.[1][4][5] WP

Rasagiline was approved for medical use in the European Union in 2005 and in the United States in 2006. Generic versions of rasagiline are available.[1][6–10] WP

Drug class

Monoamine oxidase inhibitor Antiparkinsonian WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Parkinson's disease

Rasagiline is used to treat symptoms of Parkinson's disease both alone and in combination with other drugs. It has shown efficacy in both early and advanced Parkinson's, and appears to be especially useful in dealing with non-motor symptoms like fatigue.[1][11][12] WP

Teva conducted clinical trials attempting to prove that rasagiline did not just treat symptoms, but was a disease-modifying drug—that it actually prevented the death of the dopaminergic neurons that characterize Parkinson's disease and slowed disease progression. They conducted two clinical trials, called TEMPO and ADAGIO, to try to prove this. The United States Food and Drug Administration (FDA) advisory committee rejected their claim in 2011, saying that the clinical trial results did not prove that rasagiline was neuroprotective. The main reason was that in one of the trials, the lower dose (1 mg) was effective at slowing progression, but the higher dose (2 mg) was not, contradicting standard dose-response pharmacology.[13][14] WP

MAO-B inhibitors like rasagiline may improve certain non-motor symptoms in Parkinson's disease. These may include depression, sleep disturbances, and pain (particularly related to motor fluctuations), but are unlikely to include cognitive or olfactory dysfunctions. The effects of MAO-B inhibitors like rasagiline on fatigue, autonomic dysfunctions, apathy, and impulse control disorders in people with Parkinson's disease remain unknown. Rasagiline has been reported to significantly improve quality of life in people with Parkinson's disease, but the effect sizes were trivial to small and may not be clinically meaningful. It showed a large effect size relative to placebo for depression in people with Parkinson's disease. In other studies, rasagiline appeared to reduce fatigue in people with Parkinson's disease. However, its effect sizes for this effect in a large trial were described as trivial.[15–18] WP

Available forms

Rasagiline is available in the form of 0.5 and 1 mg oral tablets.[1][8] WP

Risks and side effects

Contraindications

Contraindications of rasagiline include concomitant use of serotonergic antidepressants (e.g., SSRI (selective serotonin reuptake inhibitors), SNRIs (serotonin–norepinephrine reuptake inhibitors), SARIs (serotonin antagonists and reuptake inhibitors), TCAs (tricyclic antidepressants), TeCAs (tetracyclic antidepressants)), pethidine (meperidine), tramadol, methadone, propoxyphene, dextromethorphan (DXM), St. John's wort, cyclobenzaprine, and other monoamine oxidase inhibitors (MAOIs). This is due to possible risk of complications such as serotonin syndrome when such medications are combined with MAOIs like rasagiline. There should be a 14-day washout period between use of rasagiline and these medications. Consumption of food with very high amounts of tyramine such as certain aged cheeses should also be avoided while on rasagiline due to risk of hypertensive crisis. Rasagiline is contraindicated in people with moderate or severe hepatic impairment.[1][19] WP

Side effects

The FDA label contains warnings that rasagiline may cause severe hypertension or hypotension, may make people sleepy, may make motor control worse in some people, may cause hallucinations and psychotic-like behavior, may cause impulse control disorders, may increase the risk of melanoma, and upon withdrawal, may cause high fever or confusion.[1] WP

Side effects when the drug is taken alone include flu-like symptoms, joint pain, depression, stomach upset, headache, dizziness, and insomnia. When taken with levodopa, side effects include increased movement problems, accidental injury, sudden drops in blood pressure, joint pain and swelling, dry mouth, rash, abnormal dreams and digestive problems including vomiting, loss of appetite, weight loss, abdominal pain, nausea, and constipation. When taken with Parkinson's drugs other than levodopa, side effects include peripheral edema, fall, joint pain, cough, and insomnia.[1] WP

In a 2013 meta-analysis, none of the most frequently reported side effects of rasagiline occurred significantly more often than with placebo. It was concluded that rasagiline is well-tolerated.[20] WP

Rasagiline has been found to produce orthostatic hypotension as a side effect. Rates of orthostatic hypotension in a selection of different clinical trials have been 1.2- to 5-fold higher than those of placebo, ranging from 3.1 to 44% with rasagiline and 0.6 to 33% with placebo. Orthostatic hypotension tends to be worst in the first 2 months of treatment and then tends to decrease with time. Rasagiline can also cause hypotension while supine and unrelated to standing. In a clinical trial, the rate of hypotension was 3.2% with rasagiline versus 1.3% with placebo.[1][21] WP

Rarely, rasagiline has been reported to induce impulse control disorders, obsessive–compulsive symptoms, hypersexuality, and spontaneous orgasm or ejaculation. Other rare adverse effects associated with rasagiline include pleurothotonus (Pisa syndrome), livedo reticularis, tendon rupture, and hypoglycemia.[22–40] WP

Serotonin syndrome has been reported rarely with rasagiline both alone and in combination with selective serotonin reuptake inhibitors (SSRIs) like escitalopram, paroxetine, and sertraline and other MAOIs like linezolid.[41–48] WP

A withdrawal syndrome associated with rasagiline has been reported.[49] WP

Overdose

Rasagiline has been studied at single doses of up to 20 mg and at repeated doses of up to 10 mg/day and was well-tolerated at these doses. However, in a dose-escalation study with concomitant levodopa therapy, a dosage of 10 mg/day rasagiline was associated with cardiovascular side effects including hypertension and orthostatic hypotension in some people. The symptoms of rasagiline overdose may be similar to the case of non-selective MAOIs. Onset of symptoms may be delayed by 12 hours and may not peak for 24 hours. A variety of different symptoms may occur and the central nervous system and cardiovascular system are prominently involved. Death may result and immediate hospitalization is warranted. Serotonin syndrome has occurred with rasagiline overdose and body temperature should be monitored closely. There is no specific antidote for overdose and treatment is supportive and based on symptoms.[1][50][51][52] WP

Interactions

Interactions

Rasagiline is contraindicated with known serotonergic agents like selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), triazolopyridines or serotonin antagonists and reuptake inhibitors (SARIs) like trazodone, and other monoamine oxidase inhibitors (MAOIs), as well as meperidine (pethidine), tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, and cyclobenzaprine, due to potential risk of serotonin syndrome. However, the risk appears to be low, based on a large study of 1,504 people which looked for serotonin syndrome in people with Parkinson's disease who were treated with rasagiline plus antidepressants, rasagiline without antidepressants, or antidepressants plus Parkinson's drugs other than either rasagiline or selegiline, and in which no cases were identified.[1][11][53] WP

There is a risk of psychosis or bizarre behavior if rasagiline is used with dextromethorphan.[1] WP

There is a risk of non-selective MAO inhibition and hypertensive crisis if rasagiline is used with other MAOIs.[1] WP

Rasagiline may have a risk of hypertensive crisis in combination with sympathomimetic agents such as amphetamines, ephedrine, epinephrine, isometheptene, and pseudoephedrine. However, based on widespread clinical experience with the related selective MAO-B inhibitor selegiline, occasional use of over-the-counter sympathomimetics like pseudoephedrine appears to pose minimal risk of hypertensive crisis. In any case, the combination of sympathomimetics with MAO-B inhibitors like rasagiline and selegiline should be undertaken with caution.[53] WP

Pharmacology

Monoamine oxidase inhibitor

Parkinson's disease is characterized by the death of cells that produce dopamine, a neurotransmitter. An enzyme called monoamine oxidase (MAO) breaks down neurotransmitters. MAO has two forms, MAO-A and MAO-B. MAO-B is involved in the metabolism of dopamine. Rasagiline prevents the breakdown of dopamine by irreversibly binding to MAO-B. Dopamine is therefore more available, somewhat compensating for the diminished quantities made in the brains of people with Parkinson's disease.[11] WP

Rasagiline acts as a selective and potent irreversible inhibitor of the monoamine oxidases (MAO) enzymes monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A). It is selective for inhibition of MAO-B over MAO-A, but can also inhibit MAO-A at high doses or concentrations. MAO-B is involved in the metabolism of the monoamine neurotransmitter dopamine in the body and brain. By inhibiting MAO-B, rasagiline is thought to increase dopamine levels. In the case of Parkinson's disease, increased dopamine levels in the striatum are thought to be responsible for rasagiline's therapeutic effectiveness in treating the condition.[1][53] WP

Rasagiline inhibits platelet MAO-B activity with single doses by 35% one-hour after 1 mg, 55% after 2 mg, 79% after 5 mg, and 99% after 10 mg in healthy young people. With all dose levels, maximum inhibition is maintained for at least 48 hours after the dose. With repeated doses, rasagiline reaches greater than 99% platelet MAO-B inhibition after 6 days of 2 mg/day, 3 days of 5 mg/day, and 2 days of 10 mg/day. Similarly, repeated administration of 0.5, 1, and 2 mg/day rasagiline resulted in complete MAO-B inhibition. Clinically relevant inhibition of MAO-B is thought to require 80% inhibition and above. Following the last dose, platelet MAO-B levels remain significantly inhibited for 7 days and return to baseline after 2 weeks. In people with Parkinson's disease, rasagiline at a dose of 1 mg/day achieved near-complete inhibition of platelet MAO-B after 3 days of dosing. The recommended dosing schedule of rasagiline in Parkinson's disease (1 mg/day) has been described as somewhat questionable and potentially excessive from a pharmacological standpoint.[1][52–55] WP

The half-time for recovery of brain MAO-B following discontinuation of an MAO-B inhibitor (specifically selegiline) has been found to be approximately 40 days. Similarly, recovery of brain MAO-B following rasagiline discontinuation was gradual and occurred over 6 weeks. The clinical effectiveness of rasagiline in Parkinson's disease has been found to persist during a 6-week washout phase with discontinuation of the medication.[53][56][57] WP

Rasagiline is about 30 to 100 times more potent in inhibiting MAO-B than MAO-A in vitro and is about 17 to 65 times more potent in inhibiting MAO-B over MAO-A in vivo in rodents. Rasagiline does not importantly potentiate the pressor effects of tyramine challenge in humans, indicating that it is selective for MAO-B inhibition and does not meaningfully inhibit MAO-A. It is expected that at sufficiently high doses rasagiline would eventually become non-selective and additionally inhibit MAO-A in humans. However, it is unknown what dose threshold would be required for this to occur.[1][53] WP⚠ A word may be missing here. It reads this way in the source too.

Rasagiline is the R(+)-enantiomer of AGN-1135, a racemic mixture of rasagiline (TVP-1012) and the S(–)-enantiomer (TVP-1022). Virtually all of the MAO-inhibiting activity of AGN-1135 lies in the R(+)-enantiomer rasagiline, with this enantiomer having 1,000-fold greater inhibitory potency of MAO-B than the S(–)-enantiomer. In addition, the S(–)-enantiomer is poorly selective for MAO-B over MAO-A. As a result, the purified R(+)-enantiomer rasagiline was the form of the compound advanced for clinical development.[53][54] WP

Selegiline was the first selective MAO-B inhibitor. Selegiline and rasagiline have similar selectivity for inhibition of MAO-B over MAO-A. However, rasagiline is 5- to 10-fold more potent than selegiline at inhibiting MAO-B, which results in the former being used at lower doses clinically than the latter (1 mg/day versus 5–10 mg/day, respectively). In addition, selegiline is metabolized into levomethamphetamine and levoamphetamine. These metabolites induce the release of norepinephrine and dopamine, have sympathomimetic and psychostimulant effects, and may contribute to the effects and side effects of selegiline. In contrast to selegiline, rasagiline does not convert into metabolites with amphetamine-like effects. The amphetamine metabolites of selegiline may contribute to significant clinical differences between selegiline and rasagiline.[4][53][58–61] WP

Rasagiline metabolizes into (R)-1-aminoindan which has no amphetamine-like effects and shows neuroprotective properties in cells and in animal models.[6] WP

Selective MAO-B inhibitors including rasagiline and selegiline have been found to increase dopamine levels in the striatum in rats in vivo. It has been theorized that this might be due to strong inhibition of the metabolism of β-phenylethylamine, which is an endogenous MAO-B substrate that has monoaminergic activity enhancer and norepinephrine–dopamine releasing agent actions. β-Phenylethylamine has been described as "endogenous amphetamine" and its brain levels are dramatically increased (10- to 30-fold) by MAO-B inhibitors like selegiline. Elevation of β-phenylethylamine may be involved in the effects of MAO-B inhibitors in the treatment of Parkinson's disease.[62–68] WP

In 2021, it was discovered that MAO-A is solely or almost entirely responsible for striatal dopamine catabolism in the rodent brain and that MAO-B is not importantly involved. In contrast, MAO-B appears to mediate tonic γ-aminobutyric acid (GABA) synthesis from putrescine in the striatum, a minor and alternative metabolic pathway of GABA synthesis, and this synthesized GABA in turn inhibits dopaminergic neurons in this brain area. MAO-B specifically mediates the transformations of putrescine into γ-aminobutyraldehyde (GABAL or GABA aldehyde) and N-acetylputrescine into N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde), metabolic products that can then be converted into GABA via aldehyde dehydrogenase (ALDH) (and an unknown deacetylase enzyme in the case of N-acetyl-GABAL). These findings may warrant a rethinking of the pharmacological actions of MAO-B inhibitors like selegiline and rasagiline in the treatment of Parkinson's disease.[69–73] WP

Other actions

Rasagiline is selective for inhibition of MAOs over interactions with other proteins, including α-adrenergic receptors, β-adrenergic receptors, muscarinic acetylcholine receptors, and other targets.[53][59] WP

The major metabolite of rasagiline, (R)-1-aminoindan, is either devoid of MAO inhibition or shows only weak inhibition of MAO-B. It also has no amphetamine-like activity. However, 1-aminoindan is not lacking in pharmacological activity. Like rasagiline, 1-aminoindan shows neuroprotective activity in some experimental models. In addition, 1-aminoindan has been found to enhance striatal dopaminergic neurotransmission and improve motor function independent of MAO inhibition in animal models of Parkinson's disease.[53][55] WP

2-Aminoindan, a closely related positional isomer of 1-aminoindan, is known to inhibit the reuptake and induce the release of dopamine and norepinephrine and to produce psychostimulant-like effects in rodents, albeit with lower potency than amphetamine, but rasagiline does not metabolize into this compound. 1-Aminoindan has been found to inhibit the reuptake of norepinephrine 28-fold less potently than 2-aminoindan and to inhibit the reuptake of dopamine 300-fold less potently than 2-aminoindan, with IC₅₀ (half maximal inhibitory concentration) values for dopamine reuptake inhibition in one study of 0.4 μM for amphetamine, 3.3 μM for 2-aminoindan, and 1 mM for 1-aminoindan. In contrast to 2-aminoindan, which increased locomotor activity in rodents (+49%), 1-aminoindan suppressed locomotor activity (–69%). On the other hand, 1-aminoindan has been found to enhance the psychostimulant-like effects of amphetamine in rodents.[74–77] WP

Whereas selegiline is a catecholaminergic activity enhancer, which may be mediated by agonism of the TAAR1, rasagiline does not possess this action. Instead, rasagiline actually antagonizes selegiline's effects as a catecholaminergic activity enhancer, which may be mediated by TAAR1 antagonism.[5][65][78][79] WP

Rasagiline has been reported to directly bind to and inhibit glyceraldehyde-3-phosphate dehydrogenase (GAPDH). This might play a modulating role in its clinical effectiveness for Parkinson's disease. Selegiline also binds to and inhibits GAPDH.[4][80] WP

Rasagiline has been found to bind reversibly to α-synuclein, a major protein involved in the pathophysiology of Parkinson's disease, and this action might be neuroprotective.[81][82][83] WP

Absorption

Rasagiline is rapidly absorbed from the gastrointestinal tract with oral administration and has approximately 36% absolute bioavailability. The peak and area-under-the-curve levels of rasagiline are linear and dose-proportional over a dose range of 0.5 to 10 mg. The time to peak levels of rasagiline is 0.5 to 0.7 hours and steady-state peak levels are on average 8.5 ng/mL.[1][53] WP

At steady-state, the time to peak levels of rasagiline's major metabolite (R)-1-aminoindan is 2.1 hours, its peak levels are 2.6 ng/mL, and its area-under-the-curve levels are 10.1 ng/h/mL.[53] WP

Taking rasagiline with food (as a high-fat meal) increases peak levels by approximately 60% and area-under-the-curve levels by approximately 20%, whereas time to peak levels is unchanged. Because exposure to rasagiline is not substantially modified, rasagiline can be taken with or without food.[1][53] WP

Distribution

The mean volume of distribution of rasagiline is 87 L or 182 to 243 L depending on the source. It readily crosses the blood–brain barrier and enters the central nervous system.[1][53] WP

The plasma protein binding of rasagiline is 60 to 70% or 88 to 94% depending on the source. In the case of the latter range, 61 to 63% of binding was to albumin.[1][53] WP

Metabolism

Rasagiline is extensively metabolized in the liver. It is metabolized primarily by hepatic N-dealkylation via the cytochrome P450 enzyme CYP1A2 which forms the major metabolite (R)-1-aminoindan. It is also metabolized by hydroxylation via cytochrome P450 enzymes to form 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI). Rasagiline and its metabolites also undergo conjugation via glucuronidation.[1][51][53] WP

Use of rasagiline should be monitored carefully in people taking other drugs that inhibit or induce CYP1A2. Variants in CYP1A2 have been found to modify exposure to rasagiline in some studies but not others. Tobacco smoking, a known inhibitor of CYP1A2, did not modify rasagiline exposure. Drug transporters may be more important in influencing the pharmacokinetics of rasagiline than metabolizing enzymes.[1][84][85] WP

Exposure to rasagiline is increased in people with hepatic impairment. In those with mild hepatic impairment, peak levels of rasagiline are increased by 38% and area-under-the-curve levels by 80%, whereas in people with moderate hepatic impairment, peak levels are increased by 83% and area-under-the-curve levels by 568%. As a result, the dosage of rasagiline should be halved to 0.5 mg/day in people with mild hepatic impairment and rasagiline is considered to be contraindicated in people with moderate to severe hepatic impairment.[1][53] WP

Elimination

Rasagiline is eliminated primarily in urine (62%) and to a much lesser extent in feces (7%). Rasagiline is excreted unchanged in urine at an amount of less than 1%. Hence, it is almost completely metabolized prior to excretion.[1][53] WP

The elimination half-life of rasagiline is 1.34 hours. At steady-state, its half-life is 3 hours. As rasagiline acts as an irreversible inhibitor of MAO-B, its actions and duration of effect are not dependent on its half-life or sustained concentrations in the body.[1][53] WP

The oral clearance of rasagiline is 94.3 L/h and is similar to normal liver blood flow (90 L/h). This indicates that non-hepatic mechanisms are not significantly involved in the elimination of rasagiline.[53] WP

Moderate renal impairment did not modify exposure to rasagiline, whereas that of (R)-1-aminoindan was increased by 1.5-fold. Since (R)-1-aminoindan is not an MAO inhibitor, mild to moderate renal impairment does not require dosage adjustment of rasagiline. No data are available in the case of severe or end-stage renal impairment.[1] WP

Research

Neurodegenerative diseases

Rasagiline was under development for the treatment of Alzheimer's disease. However, development was discontinued.[86] WP

Rasagiline was tested for efficacy in people with multiple system atrophy in a large randomized, placebo-controlled, double-blind disease-modification trial; the drug failed.[12][87] WP

Rasagiline has been reported to improve symptoms in people with freezing gait.[88][89] WP

Rasagiline has been studied in the treatment of amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).[90–93] WP

Psychiatric disorders

Rasagiline has been described as an emerging potential antidepressant. MAO-B inhibitors have been found to reduce depressive symptoms in people with Parkinson's disease with a small effect size. However, rasagiline does not appear to have been studied in the treatment of depression in people without Parkinson's disease and it has not been developed nor approved for the treatment depression. In an animal study, selegiline was effective in models of antidepressant-like activity, whereas rasagiline was ineffective. The antidepressant effects of selegiline in animals appear to be independent of monoamine oxidase inhibition and may be related to its catecholaminergic activity enhancer (CAE) activity, which rasagiline lacks.[15][86][94–98] WP

Rasagiline has not been studied in the treatment of psychostimulant addiction as of 2015.[99] WP

Long COVID

People with long COVID have been found to have reduced vesicular monoamine transporter 2 (VMAT2) density, a proxy of dopaminergic nerve terminals, in several brain areas. In addition, the reductions were robustly correlated with symptoms including apathy, motor slowing, and memory loss. This has been described as the first clear biomarker of long COVID. As a result of the findings, the group responsible for the study is now evaluating rasagiline in a clinical trial as a treatment for long COVID.[100][101][102] WP

Other conditions

Rasagiline has been reported to improve restless legs syndrome (RLS).[103][104][105] WP

History

History

AGN-1135, the racemic form of the drug, was invented by Aspro Nicholas in the early 1970s. Moussa B. H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion – Israel Institute of Technology in Israel and the drug company, Teva Pharmaceuticals, identified the R-isomer as the active form of the drug. Teva brought it to market in partnership with Lundbeck in the European Union and Eisai in the United States and elsewhere.[106] WP

Prior to the discovery of rasagiline, a closely related analogue called SU-11739 (AGN-1133; J-508; N-methyl-N-propargyl-1-aminoindan) was patented in 1965. At first, the N-methyl was necessary for the agent to be considered a ring cyclized analogue of pargyline with about 20 times the potency. However, the N-methyl compound was a non-selective MAOI. In addition, SU-11739 has been reported to have strong catecholamine-releasing actions.[107][108][109] WP

Racemic rasagiline was discovered and patented by Aspro Nicholas in the 1970s as a drug candidate for treatment of hypertension.[110][111] WP

Moussa B. H. Youdim was involved in developing selegiline as a drug for Parkinson's, in collaboration with Peter Reiderer. He called the compound AGN 1135. In 1996 Youdim, in collaboration with scientists from Technion and the US National Institutes of Health, and using compounds developed with Teva Pharmaceuticals, published a paper in which the authors wrote that they were inspired by the racemic nature of deprenyl and the greater activity of one of its stereoisomers, L-deprenyl, which became selegiline, to explore the qualities of the isomers of the Aspro compound, and they found that the R-isomer had almost all the activity; this is the compound that became rasagiline. They called the mesylate salt of the R-isomer TVP-1012 and the hydrochloride salt, TVP-101.[112][113] WP

Teva and Technion filed patent applications for this racemically pure compound, methods to make it, and methods to use it to treat Parkinson's disease and other disorders, and Technion eventually assigned its rights to Teva.[110] WP

Teva began development of rasagiline, and by 1999 was in Phase III trials, and entered into a partnership with Lundbeck in which Lundbeck agreed to share the costs and obtained the joint right to market the drug in the European Union. In 2003, Teva partnered with Eisai, giving Eisai the right to jointly market the drug for Parkinson's in the US, and to co-develop and co-market the drug for Alzheimer's disease and other neurological diseases.[114][115] WP

It was approved by the European Medicines Agency for Parkinson's in 2005 and in the United States in 2006.[6][7] WP

Following its approval, rasagiline was described by some authors as a "me-too drug" that offered nothing new in terms of effectiveness and tolerability compared to selegiline. However, others have contended that rasagiline shows significant differences from and improvements over selegiline, like its lack of amphetamine metabolites and associated monoamine releasing agent effects, which may improve tolerability and safety. Conversely, others have maintained that rasagiline may be less efficacious than selegiline due to its lack of catecholaminergic activity enhancer actions.[4][5][65][116–119] WP

Legal status

Names

Rasagiline is the generic name of the drug and its INN (International Nonproprietary Name) and USAN (United States Adopted Name). It is also known by its former developmental code name TVP-1012. Rasagiline is marketed under the brand name Azilect, among others.[1][8][54][120][121] WP

Generic forms

Lower-cost generic versions of rasagiline are available.[8][9][10] WP

Chemistry

Formula

C12H13N PC

CAS number

136236-51-6 PC

Molar mass (g/mol)

171.24 PC

IUPAC name (computed by PubChem)

(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine PC

SMILES

C#CCN[C@@H]1CCC2=CC=CC=C12 PC

InChIKey

RUOKEQAAGRXIBM-GFCCVEGCSA-N PC

PubChem CID

3052776

IUPAC name

(R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Azilect- rasagiline mesylate tablet. 30 June 2020
2. Journal / agency Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs. 2007. doi:10.2165/00003495-200767120-00006 · PMID 17683172
3. Journal / agency Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs. 2008. doi:10.2165/00023210-200822070-00003 · PMID 18547126
4. Journal / agency Gerlach M, Reichmann H, Riederer P. A critical review of evidence for preclinical differences between rasagiline and selegiline. Basal Ganglia. 2012. doi:10.1016/j.baga.2012.04.032
5. Journal / agency Harsing LG, Timar J, Miklya I. Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline. International Journal of Molecular Sciences. August 2023. doi:10.3390/ijms241713334 · PMID 37686140 · PMC10487936
6. Journal / agency Schapira A, Bate G, Kirkpatrick P. Rasagiline. Nature Reviews. Drug Discovery. August 2005. doi:10.1038/nrd1803 · PMID 16106586
7. Other Silverman RB, Holladay MW. The Organic Chemistry of Drug Design and Drug Action. 29 March 2014
8. Journal / agency Drugs@FDA: FDA-Approved Drugs
9. Other Wong A, Ng C. Rasagiline (Azilect): Uses, Side Effects, Dosage & Reviews. 1 December 2021
10. Other Generic Azilect Availability. 11 July 2024
11. Journal / agency Stocchi F, Fossati C, Torti M. Rasagiline for the treatment of Parkinson's disease: an update. Expert Opinion on Pharmacotherapy. 2015. doi:10.1517/14656566.2015.1086748 · PMID 26364897
12. Journal / agency Poewe W, Mahlknecht P, Krismer F. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. Movement Disorders. September 2015. doi:10.1002/mds.26334 · PMID 26227071
13. Other Sviderski V. FDA Advisers Refuse Teva Plea to Expand Azilect Label. 19 October 2011
14. Journal / agency Katz R. Peripheral and Central Nervous System Advisory Committee Background Package on Azilect
15. Journal / agency Tsuboi T, Satake Y, Hiraga K, Yokoi K, Hattori M, Suzuki M, Hara K, Ramirez-Zamora A, Okun MS, Katsuno M. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review. npj Parkinson's Disease. June 2022. doi:10.1038/s41531-022-00339-2 · PMID 35697709 · PMC9192747
16. Journal / agency Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G. Interventions for fatigue in Parkinson's disease. The Cochrane Database of Systematic Reviews. October 2015. doi:10.1002/14651858.CD010925.pub2 · PMID 26447539 · PMC9240814
17. Journal / agency Stocchi F. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. European Journal of Neurology. February 2014. doi:10.1111/ene.12205 · PMID 23790011
18. Journal / agency Lim TT, Kluger BM, Rodriguez RL, Malaty IA, Palacio R, Ojo OO, Patel S, Gujrati Y, Nutter B, Swartz C, Hennessy C, Fernandez HH. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Movement Disorders. November 2015. doi:10.1002/mds.26429 · PMID 26769459
19. Journal / agency https://www.accessdata.fda.gov/Drugsatfda_docs/Label/2014/021641s016s017lbl.Pdf
20. Journal / agency Solís-García del Pozo J, Mínguez-Mínguez S, de Groot PW, Jordán J. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. Expert Opin Drug Saf. July 2013. doi:10.1517/14740338.2013.790956 · PMID 23634791
21. Other Rates of orthostatic hypotension in a selection of individual clinical trials presented in the rasagiline FDA label were: 13% vs. 9% with placebo, 40–44% vs. 33% with placebo, 7% vs. 3% with placebo, 9% vs. 6% with placebo, and 3.1% vs. 0.6% with placebo. In another trial, the rate of hypotension (not specifically orthostatic) was 3.2% vs. 1.3% with placebo
22. Journal / agency Vitale C, Amboni M, Erro R, Picillo M, Pellecchia MT, Barone P, Trojano L, Santangelo G. Parkinson's disease management and impulse control disorders: current state and future perspectives. Expert Review of Neurotherapeutics. June 2019. doi:10.1080/14737175.2019.1620603 · PMID 31148487
23. Journal / agency Vitale C, Santangelo G, Erro R, Errico D, Manganelli F, Improta I, Moccia M, Barone P. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. Parkinsonism & Related Disorders. April 2013. doi:10.1016/j.parkreldis.2012.11.008 · PMID 23305965
24. Journal / agency Levy A, Lang AE. Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. July 2017. doi:10.1017/cjn.2016.307 · PMID 28767029
25. Other Galvez-Jimenez, N. (2008, July). Rasagiline-and selegiline-induced hypersexuality and other impulse control disorders (ICB) in Parkinson's disease (PD): Report of 3 cases. In MOVEMENT DISORDERS (Vol. 23, No. 9, pp. 1347-1347). COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA: WILEY-BLACKWELL
26. Other Senol, M., & Kendirli, M. (2018, October). Rasagiline as Adjunctive Therapy Induced Impulse Control Disorders in Parkinson's Disease. In MOVEMENT DISORDERS (Vol. 33, pp. S832-S832). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY
27. Journal / agency Sevincok L, Kunt DA, Ozgur BG. Compulsive behaviors related to rasagiline: a case report. Journal of Clinical Psychopharmacology. August 2014. doi:10.1097/JCP.0000000000000161 · PMID 24943393
28. Journal / agency Stark R, Klucken T, Potenza MN, Brand M, Strahler J. A Current Understanding of the Behavioral Neuroscience of Compulsive Sexual Behavior Disorder and Problematic Pornography Use. Current Behavioral Neuroscience Reports. 2018. doi:10.1007/s40473-018-0162-9
29. Journal / agency Reyes D, Kurako K, Galvez-Jimenez N. Rasagiline induced hypersexuality in Parkinson's disease. Journal of Clinical Neuroscience. March 2014. doi:10.1016/j.jocn.2013.04.021 · PMID 24055209
30. Journal / agency Simonet C, Fernández B, Cerdán DM, Duarte J. Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease. Neurological Sciences. November 2016. doi:10.1007/s10072-016-2668-9 · PMID 27401808
31. Journal / agency Chen WH, Chu YH, Chen KY. Drug-Associated Spontaneous Orgasm: A Case Report and Systematic Review of Literature. Clinical Neuropharmacology. 2018. doi:10.1097/WNF.0000000000000259 · PMID 29194112
32. Journal / agency Uca AU, Kozak HH. A case of rasagiline-induced spontaneous orgasms in a female patient. Parkinsonism & Related Disorders. August 2014. doi:10.1016/j.parkreldis.2014.04.004 · PMID 24837642
33. Journal / agency Chuang RS, Lang AE. Rasagiline-induced spontaneous ejaculation. Movement Disorders. October 2009. doi:10.1002/mds.22746 · PMID 19735087
34. Journal / agency Abdel-Hamid IA, Ali OI. Spontaneous Ejaculation: A Focused Review for the Clinicians. Sexual Medicine Reviews. July 2021. doi:10.1016/j.sxmr.2020.11.001 · PMID 33262094
35. Journal / agency Solla P, Cannas A, Orofino G, Marrosu F. Rasagiline and Pisa syndrome in Parkinson's disease patients. Neurol Sci. March 2015. doi:10.1007/s10072-014-2024-x · PMID 25481627
36. Journal / agency Valentino F, Cosentino G, Fierro B, Realmuto S, Mastrilli S, Savettieri G, D'Amelio M. Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease. Neurol Sci. October 2014. doi:10.1007/s10072-014-1806-5 · PMID 24770981
37. Journal / agency Fasano A, Di Matteo A, Vitale C, Squintani G, Ferigo L, Bombieri F, Santangelo G, Amboni M, Barone P, Tinazzi M. Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. Mov Disord. December 2011. doi:10.1002/mds.23918 · PMID 22170277
38. Journal / agency Strowd LC, Lee AD, Yosipovitch G. Livedo reticularis associated with rasagiline (azilect). J Drugs Dermatol. June 2012. PMID 22648227
39. Journal / agency Lefaucheur R, Fetter D, Gaillon G, Borden A, Maltête D. Tendon rupture as an adverse effect of rasagiline. Clin Neuropharmacol. 2014. doi:10.1097/WNF.0000000000000023 · PMID 24614673
40. Journal / agency Ibrahim FA, Rashid F, Hussain AA, Alawadi F, Bashier A. Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report. J Med Case Rep. February 2017. doi:10.1186/s13256-017-1202-x · PMID 28148284 · PMC5289042
41. Journal / agency Aboukarr A, Giudice M. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. Can J Hosp Pharm. 2018. doi:10.4212/cjhp.v71i3.2586 · PMID 29955193 · PMC6019085
42. Journal / agency Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature. J Med Assoc Thai. December 2015. PMID 27004312
43. Journal / agency Hébant B, Guillaume M, Desbordes M, Gaillon G, Maltête D, Lefaucheur R. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). December 2016. doi:10.1016/j.neurol.2016.10.002 · PMID 27838092
44. Journal / agency Duval F, Flabeau O, Razafimahefa J, Spampinato U, Tison F. Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome. Mov Disord. September 2013. doi:10.1002/mds.25416 · PMID 23495033
45. Journal / agency Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. March 2011. doi:10.1002/mds.23649 · PMID 21370275
46. Journal / agency Bandrés Liso AC, Toyas Miazza C. Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram. Farm Hosp. 2009. doi:10.1016/s1130-6343(09)71160-2 · PMID 19712602
47. Journal / agency Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry. November 2009. doi:10.1016/j.pnpbp.2009.08.014 · PMID 19733607
48. Journal / agency Hisham M, Sivakumar MN, Nandakumar V, Lakshmikanthcharan S. Linezolid and Rasagiline - A culprit for serotonin syndrome. Indian J Pharmacol. 2016. doi:10.4103/0253-7613.174573 · PMID 26997732 · PMC4778217
49. Journal / agency Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, Zarbo IR, Meloni M, Sechi E, Bagella CF, Defazio G. Rasagiline Withdrawal Syndrome in Parkinson's Disease. Brain Sci. February 2022. doi:10.3390/brainsci12020219 · PMID 35203982 · PMC8870166
50. Journal / agency Rascol O. Rasagiline in the pharmacotherapy of Parkinson's disease--a review. Expert Opinion on Pharmacotherapy. October 2005. doi:10.1517/14656566.6.12.2061 · PMID 16197359
51. Journal / agency Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Therapeutics and Clinical Risk Management. June 2007. PMID 18488080 · PMC2386362
52. Journal / agency Thébault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. October 2004. doi:10.1592/phco.24.14.1295.43156 · PMID 15628826
53. Journal / agency Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Journal of Clinical Pharmacology. August 2005. doi:10.1177/0091270005277935 · PMID 16027398
54. Journal / agency Finberg JP. The discovery and development of rasagiline as a new anti-Parkinson medication. Journal of Neural Transmission. February 2020. doi:10.1007/s00702-020-02142-w · PMID 31974721
55. Journal / agency Müller T. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. Expert Opinion on Drug Metabolism & Toxicology. October 2014. doi:10.1517/17425255.2014.943182 · PMID 25196265
56. Journal / agency Malaty IA, Fernandez HH. Role of rasagiline in treating Parkinson's disease: Effect on disease progression. Ther Clin Risk Manag. August 2009. doi:10.2147/tcrm.s4321 · PMID 19753135 · PMC2695242
57. Journal / agency Freedman NM, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, Ehrlich D, Chisin R. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med. October 2005. PMID 16204711
58. Journal / agency Hoffman GR, Olson MG, Schoffstall AM, Estévez RF, Van den Eynde V, Gillman PK, Stabio ME. Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine. ACS Chemical Neuroscience. December 2023. doi:10.1021/acschemneuro.3c00591 · PMID 37966854
59. Journal / agency Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology. January 2001. doi:10.1038/sj.bjp.0703826 · PMID 11159700 · PMC1572573
60. Journal / agency Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clinical Pharmacology and Therapeutics. December 1994. doi:10.1038/clpt.1994.204 · PMID 7995016
61. Journal / agency Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. Journal of Psychopharmacology. June 2013. doi:10.1177/0269881113482532 · PMID 23539642 · PMC3666194
62. Journal / agency Finberg JP. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. Journal of Neural Transmission. April 2019. doi:10.1007/s00702-018-1952-7 · PMID 30386930
63. Journal / agency Finberg JP. Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential. Rambam Maimonides Med J. July 2010. doi:10.5041/RMMJ.10003 · PMID 23908775 · PMC3721659
64. Journal / agency Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. October 1996. doi:10.1046/j.1471-4159.1996.67041532.x · PMID 8858937
65. Journal / agency Miklya I. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Molecular Psychiatry. November 2016. doi:10.1038/mp.2016.127 · PMID 27480491
66. Journal / agency Youdim MB, Tipton KF. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord. March 2002. doi:10.1016/s1353-8020(01)00011-6 · PMID 12039419
67. Journal / agency Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. April 2006. doi:10.1038/nrn1883 · PMID 16552415
68. Journal / agency Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurologica Scandinavica. Supplementum. 1991. doi:10.1111/j.1600-0404.1991.tb05020.x · PMID 1686954
69. Journal / agency Nadeem MS, Hosawi SB, Murtaza BN, Kazmi I. How Synthetic Drugs Work: Insights Into Molecular Pharmacology of Classic and New Pharmaceuticals. 2023. doi:10.1016/b978-0-323-99855-0.00009-9
70. Journal / agency Nam MH, Sa M, Ju YH, Park MG, Lee CJ. Revisiting the Role of Astrocytic MAOB in Parkinson's Disease. International Journal of Molecular Sciences. April 2022. doi:10.3390/ijms23084453 · PMID 35457272 · PMC9028367
71. Journal / agency Cho HU, Kim S, Sim J, Yang S, An H, Nam MH, Jang DP, Lee CJ. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis. Experimental & Molecular Medicine. July 2021. doi:10.1038/s12276-021-00646-3 · PMID 34244591 · PMC8333267
72. Journal / agency Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. A Survey of Cell Biology. Int Rev Cytol. 2002. doi:10.1016/s0074-7696(02)13011-7 · PMID 11837891
73. Journal / agency Seiler N. Catabolism of polyamines. Amino Acids. June 2004. doi:10.1007/s00726-004-0070-z · PMID 15221502
74. Journal / agency Pinterova N, Horsley RR, Palenicek T. Synthetic Aminoindanes: A Summary of Existing Knowledge. Frontiers in Psychiatry. 2017. doi:10.3389/fpsyt.2017.00236 · PMID 29204127 · PMC5698283
75. Journal / agency Brandt SD, Braithwaite RA, Evans-Brown M, Kicman AT. Novel Psychoactive Substances. 2013. doi:10.1016/b978-0-12-415816-0.00011-0
76. Journal / agency Speiser Z, Levy R, Cohen S. MAO — the Mother of all Amine Oxidases. Journal of Neural Transmission. Supplementum. 1998. doi:10.1007/978-3-7091-6499-0_29 · PMID 9564629
77. Journal / agency Horn AS, Snyder SH. Steric requirements for catecholamine uptake by rat brain synaptosomes: studies with rigid analogs of amphetamine. The Journal of Pharmacology and Experimental Therapeutics. March 1972. doi:10.1016/S0022-3565(25)29135-2 · PMID 5012779
78. Journal / agency Miklya I. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacological Reports. June 2014. doi:10.1016/j.pharep.2013.11.003 · PMID 24905523
79. Journal / agency Berry MD. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Reviews on Recent Clinical Trials. January 2007. doi:10.2174/157488707779318107 · PMID 18473983
80. Journal / agency Deftereos SN, Andronis CA. Discordant effects of rasagiline doses in Parkinson disease. Nat Rev Neurol. July 2010. doi:10.1038/nrneurol.2010.2-c1 · PMID 20653097
81. Journal / agency Oliveri V. Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation. European Journal of Medicinal Chemistry. April 2019. doi:10.1016/j.ejmech.2019.01.045 · PMID 30743095
82. Journal / agency Kakish J, Lee D, Lee JS. Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?. ACS Chemical Neuroscience. December 2015. doi:10.1021/acschemneuro.5b00172 · PMID 26378986
83. Journal / agency Kakish J, Tavassoly O, Lee JS. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein. ACS Chemical Neuroscience. February 2015. doi:10.1021/cn5002914 · PMID 25514361
84. Journal / agency Bilal R, Ahmad NS, Zaffar S, Mazhar MU, Siddiqui WA, Tariq S. Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses. Pak J Med Sci. 2022. doi:10.12669/pjms.38.3.4940 · PMID 35480532 · PMC9002453
85. Journal / agency Zubiaur P, Matas M, Martín-Vílchez S, Soria-Chacartegui P, Villapalos-García G, Figueiredo-Tor L, Calleja S, Navares-Gómez M, de Miguel A, Novalbos J, Mejía-Abril G, Luquero-Bueno S, Román M, Ochoa D, Abad-Santos F. Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline. Pharmaceutics. September 2022. doi:10.3390/pharmaceutics14102001 · PMID 36297437 · PMC9610285
86. Journal / agency Rasagiline - Teva Pharmaceutical Industries. 5 November 2023
87. Journal / agency Palma JA, Kaufmann H. Novel therapeutic approaches in multiple system atrophy. Clin Auton Res. February 2015. doi:10.1007/s10286-014-0249-7 · PMID 24928797 · PMC4265580
88. Journal / agency Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008. doi:10.1002/mds.21914 · PMID 18668620
89. Journal / agency Coria F, Cozar-Santiago Mdel P. Rasagiline improves freezing in a patient with primary progressive freezing gait. Mov Disord. February 2008. doi:10.1002/mds.21868 · PMID 18067186
90. Journal / agency Dorst J, Genge A. Clinical studies in amyotrophic lateral sclerosis. Curr Opin Neurol. October 2022. doi:10.1097/WCO.0000000000001099 · PMID 35942672
91. Journal / agency Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. February 2019. doi:10.1002/mus.26335 · PMID 30192007 · PMC6545236
92. Journal / agency Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Wollebæk Johannesen S, Göricke B. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. August 2018. doi:10.1016/S1474-4422(18)30176-5 · PMID 29934198
93. Journal / agency Rato ML, Duarte GS, Mestre T, de Carvalho M, Ferreira JJ. Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurol. October 2018. doi:10.1016/S1474-4422(18)30310-7 · PMID 30264722
94. Journal / agency Fasipe OJ. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. June 2019. doi:10.1016/j.ibror.2019.01.001 · PMID 31211282 · PMC6562183
95. Journal / agency Huang YH, Chen JH, Loh EW, Chan L, Hong CT. The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials. Ther Adv Psychopharmacol. 2021. doi:10.1177/2045125320985993 · PMID 33520156 · PMC7816524
96. Journal / agency rasagiline[title] (depress*[title] OR antidepress*[title] OR dysthym*[title])
97. Journal / agency Knoll J, Zelena D, Timar J, Baghy K, Mervai Z, Miklya I. Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response. Behav Brain Res. January 2020. doi:10.1016/j.bbr.2019.112290 · PMID 31610214
98. Journal / agency Ishikawa T, Okano M, Minami A, Tsunekawa H, Satoyoshi H, Tsukamoto Y, Takahata K, Muraoka S. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. Behav Brain Res. February 2019. doi:10.1016/j.bbr.2018.10.032 · PMID 30359642
99. Journal / agency McCreary AC, Müller CP, Filip M. Psychostimulants: Basic and Clinical Pharmacology. Int Rev Neurobiol. 2015. doi:10.1016/bs.irn.2015.02.008 · PMID 26070753
100. Journal / agency Liu YK, Persaud D, Vieira EL, Braga J, Rusjan P, Miler L, Rabin JS, McCluskey T, Boileau I, Chao T, Bagby M, Narciso L, Gray LR, Vasdev N, Desmond K, Kloiber S, Warsh J, Husain MI, Smart K, Wang W, Meyer JH. Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms. eBioMedicine. August 2026. doi:10.1016/j.ebiom.2026.106339 · PMID 42431745 · PMC13476897
101. Other Gioino, Catherina. Long COVID's brain fog finally has a biological explanation: Dopamine loss. 14 September 2026
102. Other Ferruggia, Kennedy. Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments. 16 September 2026
103. Journal / agency de Biase S, Pellitteri G, Gigli GL, Valente M. Advancing synthetic therapies for the treatment of restless legs syndrome. Expert Opinion on Pharmacotherapy. November 2019. doi:10.1080/14656566.2019.1654997 · PMID 31424287
104. Journal / agency Babacan-Yildiz G, Gursoy E, Kolukisa M, Celebi A. Restless legs syndrome responsive to rasagiline treatment: a case report. Clinical Neuropharmacology. 2012. doi:10.1097/WNF.0b013e31824c1c3f · PMID 22421586
105. Journal / agency Alvarez M, Grogan P. A Tale of Two Restless Sisters (P02.067). Neurology. 12 February 2013. doi:10.1212/WNL.80.7_supplement.P02.067
106. Journal / agency Lakhan SE. From a Parkinson's disease expert: Rasagiline and the future of therapy. Molecular Neurodegeneration. July 2007. doi:10.1186/1750-1326-2-13 · PMID 17617893 · PMC1929084
107. Journal / agency Huebner CF, Donoghue EM, Plummer AJ, Furness PA. N-methyl-n-2-propynyl-l-indanamine. A protent monoamine oxidase inhibitor. Journal of Medicinal Chemistry. November 1966. doi:10.1021/jm00324a009 · PMID 5972038
108. Journal / agency Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British Journal of Pharmacology. January 2006. doi:10.1038/sj.bjp.0706464 · PMID 16402116 · PMC1760741
109. Journal / agency Miklya I. (-)-deprenil, az N-metilprogargilamin-1-aminoindan (J-508) és a J-508 dezmetil analógjának (rasagilin) összehasonlító farmakológiai analízise. Neuropsychopharmacol Hung. March 2008. PMID 18771016
110. Other Methods of lowering blood pressure in animals by administering secondary and tertiary amines
111. Other Teva v Watson
112. Other Sielg-Itzkovich J. Making armor for the brain. 13 November 2010
113. Journal / agency Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Deprenyl — Past and Future. Journal of Neural Transmission. Supplementum. 1996. doi:10.1007/978-3-7091-7494-4_9 · PMID 8988465
114. Journal / agency Kupsch A. Rasagiline. Teva Pharmaceutical. Current Opinion in Investigational Drugs. May 2002. PMID 12090555
115. Other Teva and Eisai Sign Agreement for Co-development of Rasagiline for Alzheimer's disease, and Co-promotion for Parkinson's Disease, in the U.S. 15 May 2003
116. Journal / agency Knudsen Gerber DS. Selegiline and rasagiline: twins or distant cousins?. Consult Pharm. January 2011. doi:10.4140/TCP.n.2011.48 · PMID 21224199
117. Journal / agency Rasagiline. Parkinson's disease: a simple me-too. Prescrire Int. December 2006. PMID 17167927
118. Journal / agency Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Br J Clin Pharmacol. September 2018. doi:10.1111/bcp.13651 · PMID 29847694 · PMC6089809
119. Journal / agency Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol. February 1998. doi:10.1111/j.1600-0773.1998.tb01399.x · PMID 9498233
120. Journal / agency Rasagiline
121. Other Rasagiline. 21 July 2022

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.